Investigating the effect of magnesium supplement in patients with major depressive disorder under selective serotonin reuptake inhibitor treatment
Nazarinasab M, Behrouzian F, Abdi L, Sadegh Moghaddam AA, Sadeghi S
Journal of family medicine and primary care · 7 citations
How it was studied
- Design
- Randomized controlled trial (classified by our AI screen)
- Studied in
- People
- Main outcome
- Health markers and function
Who paid for it
- Funding
- Independent funding
Based on full-text disclosure statement.
Publication
- Published
- 2022-12-01 · J Family Med Prim Care · vol. 11 · issue 12 · pp. 7800–7805
- Publisher
- Medknow
- Cited
- 7 citations · more than 67% of similar papers · 0.7× the field average
- References
- 24 works
- Access
- Open access (journal) · CC-BY-NC-SA
- Research areas
- Magnesium in Health and Disease · Thallium and Germanium Studies · Cardiac Health and Mental Health
- Keywords
- Medicine, Major depressive disorder, Serotonin reuptake inhibitor, Internal medicine, Fluoxetine, Randomized controlled trial, Anxiety, Depression (economics), Mood, Psychiatry, Placebo, Beck Depression Inventory, Mood disorders, Antidepressant, Serotonin
5 authors
From IR
- Masoumeh Nazarinasab · correspondingAhvaz Jundishapur University of Medical Sciences
- Forouzan BehrouzianAhvaz Jundishapur University of Medical Sciences
- Leila AbdiAhvaz Jundishapur University of Medical Sciences
- Amir Ali Sadegh MoghaddamAhvaz Jundishapur University of Medical Sciences
- Susan SadeghiAhvaz Jundishapur University of Medical Sciences
Abstract
Background
Major depression disorder (MDD) is a mental disorder that affects millions of people worldwide. This disease has negative impacts on quality of life and psychological-related functions. This is a multifactorial disorder; both genetic background and environmental factors have their role. Antidepressants are prescribed as the first line of treatment for patients with depressive disorders. Selective serotonin reuptake inhibitor (SSRI) antidepressants are used to treat MDD and anxiety; however, some patients do not respond to them. Regarding that, magnesium plays a major role in mood regulation; therefore, this study aimed to investigate the role of magnesium supplement in patients with MDD and under an SSRI treatment regimen.
Methods
In this randomized, double-blind controlled trial, 60 patients with major depressive disorders based on the DSM-V diagnosis referred to Golestan Hospital in Ahvaz, Iran, were included. The eligible patients were categorized randomly into two thirty-people groups receiving magnesium (intervention) and placebo (control) along with SSRI for 6 weeks. To evaluate the depression status, the Beck II test was applied. Subjects were examined before and after the intervention.
Results
There was no statistically significant difference between the two groups in terms of demographic characteristics (P > 0.05). The mean Beck scores at the beginning of the study and the second week after the intervention were not different between the two groups (P = 0.97, P = 0.56), whereas the mean Beck scores were lower in the intervention group than in the control group in the fourth and sixth weeks after the intervention (P = 0.02 and P = 0.001, respectively).
Conclusion
Administration of Mg supplement for at least 6 weeks might improve depression symptoms. It can also be considered as a potential adjunct treatment option for MDD patients who are under SSRI treatment.
Abstract via Europe PMC. Copyright remains with the authors or publisher (CC BY-NC-SA).
Community trust
Loading…
How much do you trust this study's findings?
Comments
Sign in to rate, comment on or flag this study.Sign inSomething wrong here?
Flag this study if its information, labels or funding look wrong. An editor reviews every flag.
Sign in to rate, comment on or flag this study.Sign inEducational information about published research. Not medical advice, and not a recommendation to start or stop anything.